Treatment success with pulsed field ablation was higher at 1 year than with antiarrhythmic drug therapy for patients with persistent atrial fibrillation.

In patients with persistent atrial fibrillation, those receiving pulsed field ablation as first-line therapy had less risk ...

With CMS’ recent approval of electrophysiology ablation procedures for the ASC setting, leaders are faced with a range of new ...

AVANT GUARD trial meets expectations despite pause for safety modifications ...

A minimally invasive heart procedure may be a better first-line treatment than medication for people living with advanced ...

Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...

Two retrospective studies detected arrhythmias beyond 48 hours in 30% of patients post cardiac ablation and in 60% of ...

Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where ...

Over the last weekend, Chicago played host to the 2026 edition of the Heart Rhythm Society's annual conference (HRS 2026).

In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.

Rhythm (Nasdaq:IRTC) today announced findings from two real-world analyses supporting its long-term heart monitoring ...